Business Context and Reporting Period
Company: iBio, Inc. (formerly iBioPharma, Inc.)
Filing Type: Form 10-K Annual Report
Reporting Period: Fiscal year ended June 30, 2009
Business Overview: iBio is a biotechnology company developing vaccines and therapeutic proteins using its proprietary plant-based "iBioLaunch" platform. The company spun off from Integrated BioPharma, Inc. in August 2008. Its near-term focus is advancing H1N1 influenza vaccine candidates to clinical trials and licensing its technology. Historically, the company generated revenue from nutritional supplements, but effective April 1, 2009, it licensed this business to a subsidiary of its former parent in exchange for a 5% royalty.
Key Financial Metrics
| Metric | Fiscal Year 2009 | Fiscal Year 2008 |
|---|---|---|
| Net Sales | $1,177,000 | $987,000 |
| Cost of Sales | $501,000 | $485,000 |
| Gross Margin | 58% | 51% |
| Research & Development Expenses | $797,000 | $550,000 |
| Selling & Administrative Expenses | $1,805,000 | $1,818,000 |
| Net Loss (Implied) | Significant Loss | Significant Loss |
| Cash and Cash Equivalents (June 30, 2009) | $1,039,000 | N/A |
| Accumulated Deficit (June 30, 2009) | ~$8,668,000 | N/A |
| Working Capital (June 30, 2009) | $723,000 | ($1,761,000) |
Cash Flow Summary (FY 2009):
- Operating Activities: Used $2,025,000
- Investing Activities: Used $1,617,000 (primarily for intangible assets and IP acquisition)
- Financing Activities: Provided $4,662,000 (primarily from August 2008 equity offering)
Material Changes vs. Prior Period
- Revenue Mix Shift: Sales from the former parent's subsidiary (Mannatech supply agreement) dropped from 92% of revenue in 2008 to 49% in 2009. The remaining 49% of 2009 revenue came from a subcontract with Fraunhofer USA Center for Molecular Biotechnology (FhCMB) under a DARPA grant, which concluded on June 30, 2009.
- Spin-off Impact: Corporate support charges from the former parent decreased by 93% ($291,000) as the company became independent. However, consulting and professional fees increased by 109% ($318,000) due to the costs of operating as a standalone public entity.
- R&D Increase: R&D costs rose by $247,000 (45%) primarily due to milestone payments to FhCMB.
- Liquidity Improvement: Working capital improved from a negative $1.76 million in 2008 to a positive $723,000 in 2009, driven by the August 2008 capital raise.
Guidance, Outlook, Risks, and Unusual Items
Outlook and Guidance:
Management expects existing cash resources, combined with a $3.0 million private placement closed in September 2009 (net proceeds $2.83 million), to fund operations through the fall of 2010. The company anticipates entering Phase 1 human clinical trials for at least one product candidate in calendar year 2010.
Material Commitments:
The company has a contractual commitment to pay FhCMB $2.0 million annually for five years (totaling $10.0 million) beginning in November 2009 for research and development. As of June 30, 2009, $2.0 million was due within one year.
Risks and Contingencies:
- Liquidity Risk: The company has incurred significant losses and negative cash flows. Failure to raise additional capital or secure licensing revenue could force a cessation of operations.
- Development Risk: All product candidates are in the preclinical stage. Success depends on clinical trial results and regulatory approval, which are uncertain.
- Dependency: The company relies heavily on FhCMB for R&D and manufacturing. Termination of this relationship would be materially adverse.
- Dispute: A disagreement exists with FhCMB regarding a $250,000 milestone payment as of June 30, 2009. If recognized, this would increase the 2009 loss by that amount.
Key Facts for Investor Verification
- Cash Runway: Verify if the September 2009 capital raise ($2.83M net) is sufficient to cover the $2.0M annual commitment to FhCMB starting November 2009 and ongoing operating losses.
- Revenue Sustainability: Confirm the status of the DARPA subcontract revenue ($1.035M in 2009), which ended June 30, 2009, and the timeline for generating new licensing revenue.
- Intellectual Property: Review the status of the 17 pending U.S. patent applications and 93 foreign applications, as the business model relies entirely on licensing this IP.
- Related Party Transactions: Monitor the 5% royalty arrangement with the former parent's subsidiary for nutritional supplements and the ongoing R&D payments to FhCMB.
- Stock Dilution: Note the issuance of 4.6 million shares in the September 2009 private placement and the existence of warrants issued to investors and advisors.